[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chulalongkorn University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":691},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,51,80,105,128,162,185,207,242,270,297,323,352,370,395,421,448,478,503,526,560,598,618,642,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100644494","phase-4-vitamin-d2-versus-vitamin-d2-plus-calcitriol-in-cholestatic-children-with-vitamin-d-deficiency-100644494",false,"NCT07670611","VITAMIN D2 VERSUS VITAMIN D2 PLUS CALCITRIOL IN CHOLESTATIC CHILDREN WITH VITAMIN D DEFICIENCY","ACCELERATED CORRECTION OF VITAMIN D DEFICIENCY IN CHOLESTATIC CHILDREN: A COMPARATIVE TRIAL OF VITAMIN D2 MONOTHERAPY VERSUS COMBINATION THERAPY WITH CALCITRIOL","VITD-CHOL","Inclusion Criteria:\n\n* Patients younger than 18 years of age.\n* Patients diagnosed with cholestasis, defined as direct\u002Fconjugated bilirubin \\>1 mg\u002FdL for more than 1 month.\n* Patients diagnosed with chronic liver disease.\n* Patients with vitamin D deficiency, defined as serum 25-hydroxyvitamin D (25-OHD) level \\\u003C20 ng\u002FmL, according to the Endocrine Society Clinical Practice Guideline.\n\nExclusion Criteria:\n\n* Pre-existing hypercalciuria, screened by urine calcium testing before enrollment.\n* Patients with benign or malignant tumors.\n* Patients with renal tubular defects, screened by electrolyte testing before enrollment.\n* Patients currently receiving anticonvulsant therapy.\n* Patients who do not attend scheduled follow-up visits.","ALL","18 Years",{"count":21,"type":22},54,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn whether adding calcitriol to vitamin D2 can improve vitamin D deficiency in children with cholestasis and chronic liver disease. Cholestasis is a condition in which bile flow is reduced, which can make it difficult for the body to absorb and process vitamin D. The study will also learn about the safety of using vitamin D2 together with calcitriol.\n\nThe main questions it aims to answer are:\n\n* Does vitamin D2 plus calcitriol increase blood 25-hydroxyvitamin D (25-OHD) levels more than vitamin D2 alone after 3 months of treatment?\n* Does vitamin D2 plus calcitriol help more children reach an adequate vitamin D level by 3 and 6 months?\n* What medical problems, especially high calcium or high phosphorus levels, occur during treatment?\n\nResearchers will compare children who receive vitamin D2 alone with children who receive vitamin D2 plus calcitriol to see which treatment improves vitamin D levels more effectively and safely.\n\nParticipants will:\n\n* Take vitamin D2 alone or vitamin D2 plus calcitriol as assigned by randomization\n* Visit the clinic for study assessments at the start of the study, at 3 months, and at 6 months\n* Have blood tests to measure vitamin D levels, calcium, phosphorus, parathyroid hormone, liver function, and other safety markers\n* Have their treatment reviewed at 3 months; participants whose vitamin D level remains low may have their treatment adjusted according to the study plan\n* Bring back medication packages so researchers can check how regularly the study medicines were taken",[28,29,30,31],"Cholestatic Liver Disease","Chronic Liver Disease (CLD)","Vitamin D Deficiency","Children",[33,34,35,36,37],"cholestasis","pediatrics","vitamin d deficiency","Calcitriol","25-Hydroxyvitamin D2","RECRUITING","2026-06-22",{"date":41,"type":42},"2026-06-26","ACTUAL",{"date":44,"type":42},"2026-04-28",{"date":46,"type":22},"2027-04-20",{"name":48,"class":49},"Chulalongkorn University","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100518461","phase-2-the-treatment-effects-of-empagliflozin-on-renal-outcomes-in-cardiorenal-syndrome-type-1-100518461","NCT06030843","The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1","TREAT-CRS","Inclusion criteria\n\n* Age 18 years or more\n* Hospitalized for the primary diagnosis of acute denovo or decompensated chronic heart regardless of ejection fraction\n* AKI KDIGO any stage or urine NGAL ≥ 150 ng\u002FmL\n* Must be able to be enrolled into the trial ≤ 12 hours of diagnosis of AKI or elevated urine NGAL\n\nExclusion criteria\n\n* Denied to participate in the study\n* Cardiogenic shock or unstable hemodynamic (systolic blood pressure of at least 100 mmHg or required inotropic support within last 24 hours)\n* Cardiac mechanical support (i.e. extracorporeal membrane oxygenation and intra-aortic balloon pump)\n* Acute coronary syndrome\n* Diagnosed with cause of AKI other than cardiorenal syndrome (eg. sepsis, nephrotoxic, dehydration)\n* Anuria or requiring dialysis or expected to required dialysis within 24 hr\n* Baseline eGFR ≤ 20 ml\u002Fmin\u002F1.73m2 with or without dialysis initiated\n* Heart or kidney transplanted\n* Previously received any SGLT2i in the last 3 months before admission\n* Allergic to any SGLT2i\n* Type 1 diabetes mellitus\n* History of ketoacidosis, including diabetic ketoacidosis\n* Pregnancy\n* Comorbid conditions with an expected survival of less than 1 months such as end-stage liver or heart disease, or uncurable malignancy",{"count":59,"type":22},200,[61,62],"PHASE2","PHASE3","Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.",[65],"Empagliflozin in Cardiorenal Syndrome Type 1",[67,68,69,70,71],"Empagliflozin","SGLT2i","Cardiorenal syndrome","ADHF","AKI","2026-06-15",{"date":74,"type":42},"2026-06-16",{"date":76,"type":42},"2025-03-01",{"date":78,"type":22},"2026-12-31",{"name":48,"class":49},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100487770","efficacy-of-dengue-infection-with-warning-signs-treated-with-dexamethasone-dengdex-study-100487770","NCT05631405","Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)","Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone","Inclusion Criteria:\n\n* Laboratory confirmed Dengue infected patients (Positive NS1 Ag or anti-DENV IgM by Dengue Duo test)\n* And still in febrile phase (Body temp\\>37.5 C)\n* Shock : Sys\\\u003C90mmHg or Narrow PP (\\\u003C20mmHg) orTachycardia (pulse\\>100\u002Fmin) with Hematocrit decreased ≥20 %\n* Fluid accumulation and respiratory distress\n* Severe bleeding\n* Severe organ involvement\n\nExclusion Criteria:\n\n* Severe dengue\\> 24 hrs\n* Dengue without warning signs\n* Pregnancy\n* Patient who receieved any steroid within 1 week","7 Years","99 Years",{"count":59,"type":22},[91],"NA","The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.",[94],"Severe Dengue",[94,96,97],"Dexamethasone","Steroid",{"date":74,"type":42},{"date":100,"type":42},"2022-10-16",{"date":102,"type":22},"2027-12-31",{"name":48,"class":49},2,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":50},"100441607","the-effects-of-double-plasma-molecular-adsorption-system-in-acute-on-chronic-liver-failure-patients-100441607","NCT05030571","The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients","Inclusion Criteria:\n\n1. Age 18 or more\n2. Diagnosis of Acute ontop chronic liver failure by Asian Pacific association for the study of the liver (APASL) criteria\n3. Admitted to intensive care unit\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Received steroid treatment\n3. Expected dead within 24 hour\n4. WBC \\\u003C 500\u002Fmm3\n5. Allergy to DPMAS\n6. History of organ transplant\n7. Terminal illness with do not resuscitation order",{"count":112,"type":22},40,[91],"Acute liver failure patients posed high mortality rate despite receiving standard therapy. The severity and mortality even higher in patients with underlying liver disease. Acute liver failure cause hyperinflammatory response in early stage and immunoparalysis in later stage. The surge of proinflammatory cytokines leads to multiorgan failure and more liver injury. Subsequent immunoparalysis may lead to lethal secondary infections.\n\nLiver support system had been used in acute and acute ontop chronic liver disease for last several decades. Double plasma molecular adsorption system (DPMAS) is one of the promising non-biological liver support system that have been extensively investigated in acute ontop chronic liver failure from hepatits B viral. DPMAS circuit consist of BS330 (bilirubin adsorber) and HA330 (Cytokines adsorber). Thus, DPMAS can also remove various cytokines. The effect of DPMAS on immune function in these patients has not been explored.\n\nRecent randomized controlled trial by Srisawat et al. demonstrated improvement of mHLA-DR in septic shock patients who received polymyxin B extracorporeal therapy compare to control arm. Since liver failure show change of immunological profile resemble to sepsis. Investigators proposed that removal of toxic liver toxins and lethal cytokines by DPMAS will improve immunological profiles in acute ontop chronic liver failure patients.\n\nInvestigators plan to conduct a randomized controlled trial in acute ontop chronic liver failure patients who admitted to intensive care unit. Investigators plan to compare the immunomodulatory effects of DPMAS with standard treatments.",[116,117],"Acute-On-Chronic Liver Failure","Acute on Chronic Hepatic Failure",[119,116,120,121],"Hemoperfusion","Cytokine adsorbant therapy","HA-330",{"date":74,"type":42},{"date":124,"type":42},"2021-01-01",{"date":126,"type":22},"2027-04-01",{"name":48,"class":49},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":18,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":141,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":50},"100639862","bite-force-and-occlusal-force-distribution-following-root-canal-treatment-100639862","NCT07626372","Bite Force and Occlusal Force Distribution Following Root Canal Treatment.","Changes in Bite Force and Occlusal Force Distribution Following Root Canal Treatment, Restoration, and Over Time: A Prospective Observational Study","B-FORCE RCT","Inclusion Criteria:\n\n* Premolars or molars diagnosed with pulp necrosis or previously initiate therapy with normal apical tissues, asymptomatic apical periodontitis, or chronic apical abscess without full coverage restoration.\n* Adequate remaining tooth structure for cuspal coverage restoration.\n* Presence of adjacent teeth and functional opposing natural teeth.\n* No analgesics drug effect at the time of investigation or not have taken analgesics 6 hours ago.\n\nExclusion Criteria:\n\n* Patients undergoing other dental treatments during the study period that may interfere with occlusion or bite force distribution, such as orthodontic treatment, jaw surgery, or full mouth restoration.\n* Received treatments that cause weakness of the jaw and facial muscles, such as botox injections.\n* History or symptoms of temporomandibular disorders (TMD)\n* Periodontal disease with second- or third-degree mobility\n* Teeth presenting crack lines extending into the pulp chamber floor or root canal orifices.",true,"20 Years","60 Years",{"count":140,"type":22},70,"4 Years","OBSERVATIONAL","Understanding the changes in bite force and occlusal force distribution in ETT is clinically important, as it can directly influence tooth prognosis, guide restorative treatment planning, and impact the long-term survival of the treated tooth. Therefore, this study aims to further explore changes and possible correlation in maximum bite force (MBF), occlusal force distribution and patients' subjective perception of chewing function of endodontically treated teeth after non-surgical root canal treatment, subsequent restoration, and during long-term follow-up, along with comparing to contralateral vital teeth.\n\nMethods: Patients aged 20-60 years who underwent non-surgical root canal treatment at the Graduate Endodontic Clinic, Faculty of Dentistry, Chulalongkorn University, with the following teeth indicated for endodontic treatment. Measurements of maximum bite force (MBF) of ETT and contralateral vital teeth, relative occlusal force (ROF), and questionnaire responses, are performed at the following time points: before NS-RCT, 1 month after completion of NS-RCT (before doing restoration), 3 months after crown restoration, 1, 2 and 4 years after completion of NS-RCT.\n\nDifferences in MBF and ROF over time points within subjects and differences in MBF and ROF between ETT and their contralateral vital teeth were statistically analyzed.",[145],"Endodontically Treated Teeth",[147,148,149,150,151,152],"Bite force","occlusal force distribution","Endodontically treated teeth","Chewing side preference","Endodontic restoration","Prospective study","NOT_YET_RECRUITING","2026-05-31",{"date":156,"type":42},"2026-06-04",{"date":158,"type":22},"2026-06-08",{"date":160,"type":22},"2030-10-31",{"name":48,"class":49},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":50},"100638798","effect-of-high-versus-standard-protein-intake-in-critically-ill-patients-with-acute-kidney-injury-requiring-continuous-renal-replacement-therapy-100638798","NCT07596043","Effect of High Versus Standard Protein Intake in Critically Ill Patients With Acute Kidney Injury Requiring Continuous Renal Replacement Therapy","Effect of High Versus Standard Protein Intake in Critically Ill Patients With Acute Kidney Injury Requiring Continuous Renal Replacement Therapy: A Randomized Controlled Trial (PROTEIN-CRRT)","PROTEIN-CRRT","Inclusion Criteria:\n\n* Adult (≥18 years old)\n* AKI receiving CRRT within 7 days after ICU admission\n* Achieve and tolerate calories 70% of target daily caloric requirement (20 kcal \u002Fkg\u002Fd) within 7 days after ICU admission by enteral feeding\n* Participant or their surrogates is willing and able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* Moribund or withholding of treatment\n* Kidney transplant recipient\n* Previously diagnosed end-stage kidney disease (ESKD) currently on kidney replacement therapy\n* Pregnancy or breastfeeding\n* Hepatic encephalopathy (West Haven grade 3-4)\n* Burn patients\n* Patients whom the responsible clinician felt that the patient either needed low or high protein\n* Severe complications of diabetes such as ketoacidosis, hyperosmolar coma\n* Had pre-existing neuromuscular disorders\n* Previously leg amputations",{"count":171,"type":22},56,[91],"During critical illness, patients experience a hypercatabolic state. This hypercatabolic state causes muscle wasting in patients, resulting in intensive care unit acquired weakness (ICU-AW). ICU-AW is associated with prolonged mechanical ventilation (MV) weaning, extubating failure and extended length of stay. Previously recognized risk factors for ICU-AW include shock, sepsis, multiple organ failure, hyperglycemia, and prolonged exposure to corticosteroids, sedatives, or paralytic agents.\n\nCritical illness is complicated by the development of acute kidney injury (AKI). AKI causes muscle wasting by increasing protein degradation and decreasing protein synthesis. Furthermore, patients with severe AKI often require renal replacement therapy (RRT), which contributes to additional protein loss. Studies have estimated that amino acid losses associated with RRT may range from 5 to 19 g\u002Fd, with greater losses observed in patients undergoing continuous renal replacement therapy (CRRT). AKI requiring CRRT has recently been proposed to contribute to an increased risk of ICU-AW.\n\nTherefore, critically ill patients with AKI may require increased protein intake to compensate for these metabolic alterations. However, higher protein intake, particularly during the early acute phase of critical illness, may be associated with prolonged need for RRT or delayed kidney recovery.\n\nThe objective of this trial is to compare the effects of a high protein intake versus a standard protein intake on muscle mass change in critically ill patients with AKI requiring CRRT.\n\nThe goal of this clinical trial is to learn if high protein intake (1.5-1.7 g\u002Fkg\u002Fd) can reduce ICU associated weakness in critically ill patients with AKI requiring CRRT. The main questions it aims to answer is:\n\n• Does High protein intake (1.5-1.7 g\u002Fkg\u002Fd) reduce the change in RF-CSA, as measured by ultrasonography at day 7 in critically ill patients with AKI requiring CRRT Researchers will compare drug high protein intake to standard protein intake to see if high protein intake effect on muscle mass by ultrasonography.\n\nParticipants will:\n\n* Receive high protein group (1.5-1.7 g\u002Fkg\u002Fd) in High protein group and standard protein intake (1.0-1.2 g\u002Fkg\u002Fd) in control group for 7 days\n* Rectus femoris ultrasonography was performed twice on day 1 and day 7",[175,176],"Acute Kidney Failure Stage 3","Continuous Renal Replacement Therapy (CRRT)","2026-05-12",{"date":179,"type":42},"2026-05-19",{"date":181,"type":22},"2026-07-01",{"date":183,"type":22},"2027-06-30",{"name":48,"class":49},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":136,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":206,"locationsCount":50},"100597170","multi-centred-clinico-genetic-study-of-actinic-prurigo-in-thailand-100597170","NCT07055009","Multi-centred Clinico-genetic Study of Actinic Prurigo in Thailand","Inclusion Criteria:\n\n* Thai ethnicity\n* Diagnosed with Actinic Prurigo (AP) according to the diagnostic criteria defined for this study\n* Mentally competent, able to communicate, and able to read Thai.\n* Participants receiving Thalidomide treatment must use two simultaneous methods of contraception, starting at least 4 weeks prior to initiating the medication and continuing throughout the treatment period and for at least 4 weeks after discontinuation.\n\nExclusion Criteria:\n\n* History and physical examination findings suggestive of other photodermatoses such as Lupus erythematosus, Porphyria, or Polymorphous Light Eruption, among others.\n* Elevated Epstein-Barr Virus (EBV) viral load detected in blood testing (EBV viral load will be tested in all participants).\n* Low Minimal Erythema Dose (MED) to UVB radiation as the only abnormal finding.",{"count":192,"type":22},47,"This research project investigates the clinical and genetic associations of Actinic Prurigo (AP) in the Thai population. As a rare chronic photodermatosis, AP has been observed to occur more frequently in individuals with certain genetic predispositions, particularly specific Human Leukocyte Antigen (HLA) types. Previous studies have suggested variations in clinical presentation and HLA allele distributions between Asian and Western populations.\n\nThe primary aim is to explore the relationship between clinical manifestations of AP and genetic profiles, including HLA typing, among Thai individuals. Additionally, the study seeks to examine whether different HLA types are associated with varying responses to treatment.\n\nThe study design is a cross-sectional comparative study, involving both AP patients and age-matched healthy controls. Given the rarity of the condition, patient recruitment will be conducted across four collaborating institutions:\n\nKing Chulalongkorn Memorial Hospital Siriraj Hospital Institute of Dermatology",[195],"Actinic Prurigo",[197,198,199,200],"Actinic prurigo","subtype actinic prurigo","HLA typing","genetic","2026-05-08",{"date":177,"type":42},{"date":204,"type":42},"2025-03-30",{"date":78,"type":22},{"name":48,"class":49},{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":226,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100619553","fluid-balance-guided-by-modified-venous-excess-ultrasonography-versus-standard-care-in-patients-with-acute-kidney-injury-receiving-continuous-renal-replacement-therapy-100619553","NCT07346118","Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy","Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: A Multicentre Randomised Controlled Trial","mVExUS-CRRT","Inclusion Criteria:\n\n* Adults (≥ 18 years of age)\n* Admitted to ICU\n* Acute kidney injury by KDIGO criteria\n* Initiated CRRT by at least one of the following indications for RRT initiation:\n* Serum potassium ≥ 6.0 mmol\u002FL, or\n* pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol\u002FL, or\n* Evidence of severe respiratory failure, based on a PaO2\u002FFiO2 ≤ 200 and clinical perception of volume overload, or\n* Persistent severe AKI (sCr remains \\> 50% the value recorded at randomization) for \\> 72 hours from randomization\n* Participants giving informed consent\n\nExclusion Criteria:\n\n* Refuse to participate\n* Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy\n* Kidney transplant recipient\n* Receive RRT before ICU admission within 90 days\n* Structural kidney diseases which will interfere with intrarenal doppler ultrasound e.g. renal artery stenosis, autosomal dominant polycystic kidney disease\n* Patients with previously known conditions that interfere with portal doppler assessment, namely liver cirrhosis, severe tricuspid regurgitation with structural heart disease or massive ascites.\n* Underlying disease process with a life expectancy less than 90 days\n* Pregnancy\n* Severe cardiac rhythm disturbances (tachyarrhythmia, supraventricular tachycardia)\n* Intra-cardiac shunts; Ventricle septal defect, patent foramen ovale, atrial septal defect\n* Aortic aneurysm\n* Intra-abdominal hypertension (intraabdominal pressure ≥20 mmHg)\n* Expected life expectancy \\\u003C48 hours\n* Receiving extracorporeal membrane oxygenation (ECMO)",{"count":216,"type":22},126,[91],"The goal of this randomised controlled trial is to compare the cumulative fluid balance over the first 72 h following inclusion guided by mVExUS versus standard of care in critically ill patients with acute kidney injury receiving CRKT . It will also compare the proportion of CRRT-related complications-including intradialytic hypotension and arrhythmias-between patients managed with mVExUS-guided fluid management and those receiving standard care.\n\nThe main questions it aims to answer are:\n\nDoes fluid removal rate guided by mVExUS will reduce cumulative fluid balance over the course of the first 72 h of CRRT in ICU patients compared to standard care\n\nParticipants will:\n\nGet fluid assessment by mVExUS protocol or a strandard care every 8 hours for 72 hours",[220,221,222,176,223,224,225],"AKI - Acute Kidney Injury","Fluid Balance","Acute Circulatory Failure","VExUS","Passive Leg Raising","Biomarkers \u002F Blood",[227,228,229,230,231,232,233,234],"Acute kidney injury","Fluid balance","Acute circulatory failure","Continuous kidney replacement therapy","mVExUS","Modified Venous Excess Ultrasound","Passive leg raising","Biomarker","2026-05-05",{"date":237,"type":42},"2026-05-07",{"date":181,"type":22},{"date":240,"type":22},"2029-05-01",{"name":48,"class":49},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":258,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":50},"100606757","using-a-hypotension-prediction-index-to-prevent-low-blood-pressure-during-dialysis-in-icu-patients-100606757","NCT07179705","Using a Hypotension Prediction Index to Prevent Low Blood Pressure During Dialysis in ICU Patients","Hypotension Prediction Index Guided Prevention of Intradialytic Hypotension During Intermittent Renal Replacement Therapy in Intensive Care Units","HyPIR-ICU","Inclusion Criteria:\n\n* Adults \\>18 years old\n* Diagnosed with acute kidney injury (AKI) or end-stage kidney disease (ESKD)\n* Admitted to medical ICU\n* Scheduled for PIRRT\n* Have an indwelling arterial catheter\n\nExclusion Criteria:\n\n* Severe right heart dysfunction, significant valvular disease, arrhythmias, mechanical circulatory support, absence of arterial access, no UF prescription, palliative care, or expected ICU stay \\\u003C72 hours.",{"count":251,"type":22},46,[91],"This single-center, crossover randomized controlled trial (HyPIR-ICU) investigates whether a Hypotension Prediction Index (HPI)-guided management strategy can reduce intradialytic hypotension (IDH) during prolonged intermittent renal replacement therapy (PIRRT) in critically ill patients. All participants must have an indwelling arterial catheter for continuous hemodynamic monitoring.",[255,256,257],"Intradialytic Hypotension","Intensive Care Unit ICU","Hemodialysis Patients",[259,260,261,262,263,264],"Hypotension Prediction Index (HPI)","Prolonged intermittent renal replacement therapy (PIRRT)","Slow-low efficiency dialysis","Intradialytic hypotension","Hemodynamic monitoring","Intensive Care Unit",{"date":237,"type":42},{"date":267,"type":42},"2025-10-10",{"date":78,"type":22},{"name":48,"class":49},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":136,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":50},"100633857","phase-1-safety-of-mulberry-leaf-extract-capsule-on-blood-glucose-control-in-healthy-volunteer-100633857","NCT07532135","Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteer","Inclusion Criteria:\n\n* Male or female age more than 18 years\n* No Diabetis mellitus disease and no taking diabetes medication\n* Blood sugar level less than 126 mg\u002Fdl and HbA1C less than 6.5\n* Can using Thai language\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Allergic to mulberry extract\n* Take mulberry extract in 2 weeks before participate in this study\n* Take medications that have effect on blood sugar level such as steroid in 2 weeks before participate in this study\n* Have uncontrolled disease\n* Have AST, ALT, ALP more than 3 times of normal value, or estimated Glomerular Filtration Rate less than 30 ml\u002Fmin\u002F1.73 m2)\n* Pregnancy or lactation",{"count":277,"type":22},48,[279],"PHASE1","Volunteers were divided into 2 groups: mulberry leaf extract capsule (DNJ 12mg) group and placebo group. They took the sample 3 times\u002Fday for 8 weeks. Complete blood count, Blood urea nitrogen (BUN), Creatinine, Aspartate transaminase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Fasting plasma glucose, HbA1c, and adverse effects were evaluated before and after 4 and 8 weeks.",[282,283],"Healthy Volunteers","Non Diabetic Hyperglycemia",[285,286,287,288],"Safety","mulberry","glucose","healthy","2026-04-20",{"date":291,"type":42},"2026-04-23",{"date":293,"type":42},"2025-10-01",{"date":295,"type":22},"2026-09-24",{"name":48,"class":49},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":136,"sex":18,"minAge":304,"maxAge":19,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":50},"100543594","the-efficacy-and-palatability-of-developed-polyethylene-glycol-based-formula-for-children-with-functional-constipation-100543594","NCT06357897","The Efficacy and Palatability of Developed Polyethylene Glycol-based Formula for Children With Functional Constipation","Faculty of Medicine, Chulalongkorn University","Inclusion Criteria:\n\nChildren will be enrolled in this study when they meet 2 criteria:\n\n* Age from 6 months to 18 years old\n* Children are diagnosed with FC according to ROME IV criteria\n\nExclusion Criteria:\n\nChildren will be excluded from the study if they meet any of the following criteria:\n\n* Having an organic cause of constipation such as anorectal malformations, Hirschsprung disease, myelomeningocele, hypothyroidism, etc.\n* Suspected GI obstruction\n* Receiving medication affecting bowel movement\n* Having a history of allergy to PEG and stevia.","6 Months",{"count":306,"type":22},52,[91],"This study aims to evaluate the efficacy and palatability of a developed polyethylene glycol-based formula compared with the standard polyethylene glycol (PEG) in the treatment of children with functional constipation for 8 weeks. Besides, we also aim to assess the side effects of a developed PEG-based formula as well as evaluate the change of rectal diameter from baseline at each visit between 2 groups.",[310],"Functional Constipation",[312,31,313,314],"Functional constipation","Polyethylene glycol","Palatability","2026-03-27",{"date":317,"type":42},"2026-04-02",{"date":319,"type":42},"2024-05-03",{"date":321,"type":22},"2026-12",{"name":48,"class":49},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":330,"minAge":19,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":50},"100542647","drospirenone-only-pills-and-cervical-mucus-changes-a-pre--and-post-bariatric-surgery-study-100542647","NCT06345586","Drospirenone Only Pills and Cervical Mucus Changes: A Pre- and Post-Bariatric Surgery Study","Drospirenone Only Pills and Cervical Mucus Changes in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study","Inclusion Criteria:\n\n* Thai women aged 18-45 years who are obese and had an appointment for Bariatric surgery at Chulalongkorn Hospital\n* Need contraception\n* Able to use non-hormonal contraception during the study\n* Giving consent\n\nExclusion Criteria:\n\n* Pregnancy or history of giving birth within 3 months\n* Breastfeeding within the 6 months\n* History of using DMPA within 12 months\n* History of using other types of hormonal birth control pills within 4 weeks\n* History of bilateral oophorectomy or hysterectomy\n* Suspected ovarian tumor or pathological ovarian cyst\n* Regular cigarette smoking\n* Contraindications to Drospirenone","FEMALE","45 Years",{"count":333,"type":22},16,[91],"The purpose of this study is to study the effect of Drospirenone on cervical mucus change by modified Insler score, pre-bariatric surgery and post-bariatric surgery",[337],"Contraception",[339,340,341,342,343],"Drospirenone only pills","Obesity","Bariatric surgery","Roux-en-Y gastric bypass","Cervical mucus","2026-03-17",{"date":346,"type":42},"2026-03-18",{"date":348,"type":42},"2024-04-18",{"date":350,"type":22},"2026-07",{"name":48,"class":49},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":330,"minAge":19,"maxAge":331,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":368,"leadSponsor":369,"locationsCount":50},"100542645","phase-1-pharmacokinetics-of-drospirenone-only-pills-a-pre--and-post-bariatric-surgery-study-100542645","NCT06345560","Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study","Pharmacokinetics of Drospirenone Only Pills in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study",{"count":333,"type":22},[279,61],"The purpose of this study is to investigate whether bariatric surgery affects Drospirenone only pills absorption",[337],[339,340,341,342,363,364],"Pharmacokinetics","Absorption",{"date":366,"type":42},"2026-03-19",{"date":348,"type":42},{"date":350,"type":22},{"name":48,"class":49},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":4},"100622841","early-phase-1-comparison-of-treatment-outcome-of-pulpotomy-with-versus-without-dental-operating-microscope-in-carious-mature-permanent-teeth-100622841","NCT07388862","Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent Teeth","Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent Teeth : A Randomized Controlled Trial","Inclusion Criteria:\n\n* Healthy patients aged at least 18 years old with deep or extremely deep carious lesions in mature permanent teeth diagnose with asymptomatic or symptomatic irreversible pulpitis. Diagnoses are confirmed using EPT and cold tests. Pulpal and periapical diagnoses are based on terminology from the American Association of Endodontists (AAE, 2013)20.\n* Teeth are restorable with direct composite restoration.\n\nExclusion Criteria:\n\n* Teeth with subgingival caries and\u002For clinical attachment loss more than 3 mm and probing depth more than 4 mm.\n* Negative responses to pulp sensibility tests, presence of sinus tracts, swelling, non-restorable crowns, immature roots, or no pulp exposure following complete caries removal in case of pre-operative diagnosis as asymptomatic irreversible pulpitis.\n* Patients with systemic diseases involving bleeding disorders such as hemophilia, Von Willebrand disease, platelet disorders. And patients under taking all kind of anticoagulant and anti-platelet.\n* Teeth with pulpal obliteration.\n* Necrotic pulp is found after access opening\n* Bleed cannot be stopped within 8 minutes after full pulpotomy",{"count":378,"type":22},50,[380],"EARLY_PHASE1","The goal of this \\[randomized clinical trial\\] is to evaluate the treatment outcome by assessing clinical and radiographic outcomes.\n\nThe main question it aims to answer is\n\nDo using dental operating microscope incorperated with pulpotomy procedure will have a different outcome when compare with without using.\n\nParticipants will be asked to have clinical and radiographic evaluation for evaluating the outcome every year after treatment.",[383],"Irreversible Pulpitis",[385,386,387],"Pulpotomy","treatment outcome","dental operating microscope","2026-03-16",{"date":346,"type":42},{"date":391,"type":22},"2026-02-21",{"date":393,"type":22},"2037-12-31",{"name":48,"class":49},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":50},"100628209","early-phase-1-clinical-study-of-bcma-targeted-car-t-cell-injection-in-the-treatment-of-patients-with-relapsedrefractory-multiple-myeloma-100628209","NCT07458659","Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed\u002FRefractory Multiple Myeloma","Phase Ib Clinical Study of BCMA-Targeted Chimeric Antigen Receptor T-Cell Injection (CART-BCMA) in the Treatment of Patients With Relapsed\u002FRefractory Multiple Myeloma","CART-BCMA","Inclusion Criteria:\n\n1. Age above 18 years old (inclusive), regardless of gender.\n2. Patients with multiple myeloma who have received at least three lines of treatment for multiple myeloma and have failed at least after treatment with proteasome inhibitors and immunomodulators; At least one complete cycle of each line of therapy, unless the best response to that therapy was documented as progressive disease (PD) (according to the 2016 published IMWG criteria for efficacy evaluation, Appendix 4); Patients must have PD records during or within 12 months after the last treatment or no response (no MR or better response) within 60 days after the last treatment.\n3. The presence of measurable lesions at screening was defined as any of the following:\n\n   * Serum M protein ≥ 1 g\u002FdL (≥ 10 g\u002FL)\n   * Urinary M-protein level ≥ 200 mg\u002F24 hours\n   * Serum free light chains (FLC): abnormal serum FLC ratio (\\\u003C 0.26 or \\> 1.65) with involved FLC ≥ 10 mg\u002FdL (100 mg\u002FL)\n4. ECOG Performance Status (Appendix 1) of 0-1.\n5. Expected survival time ≥ 3 months.\n6. Meets the following criteria prior to mononuclear cell apheresis:\n\n   Hematology\n   * Absolute count of lymphoid cells ≥ 0.5×109\u002FL \\[Granulocyte colony-stimulating factor (G-CSF) is allowed, but this supportive treatment shall not be received by the test subjects within 7 days before laboratory tests during the screening period\\];\n   * Absolute neutrophil count ≥ 1.0 ×109\u002FL \\[Granulocyte colony-stimulating factor (G-CSF) is allowed, but the subjects shall not receive this supportive treatment within 7 days before laboratory tests during the screening period\\];\n   * Platelet count ≥ 50×109\u002FL (subjects must not receive blood transfusion support within 7 days before the screening laboratory test);\n   * Hemoglobin ≥ 8.0 g\u002FdL (recombinant human erythropoietin is allowed) \\[subjects have not received red blood cells (RBCS) within 7 days prior to screening laboratory testing\\]; Heart\n   * Ejection function: Left ventricular ejection fraction (LVEF) ≥ 50% Lungs\n   * Oxygen saturation: A blood oxygen saturation of ≥ 91% on non-oxygen therapy Kidneys\n   * Creatinine clearance (CrCl) or glomerular filtration rate (GFR) (Cockcroft-Gault formula) ≥ 30 mL\u002Fmin Liver\n   * Total bilirubin (serum) ≤ 1.5 × ULN Patients with Gilbert's disease and a serum bilirubin level of more than 1.5 × ULN could be enrolled after approval from the sponsor\n   * AST and ALT ≤ 3× ULN Clotting\n   * PT ≤ 1.5× ULN, APTT ≤ 1.5×ULN, INR ≤ 1.5×ULN\n7. Peripheral venous access can meet the requirements of apheresis and intravenous infusion.\n8. Subjects agreed to use a reliable contraceptive method for contraception from the time they signed the informed consent form until 1 year after infusion. These include, but are not limited to: abstinence, vasectomy in men, and an implantable progestin-based contraceptive that suppresses ovulation; Intrauterine contraceptive devices; Hormone-releasing intrauterine devices; Sexual partner sterilization; Copper intrauterine devices, proper use of combined hormonal contraceptives that have been shown to inhibit ovulation; Progestin-based contraceptives that inhibit ovulation. Female subjects should be at the same time commitment to lose after 1 year not to donate eggs (eggs, oocyte) used for assisted reproduction.\n9. They should voluntarily participate in the clinical trial and sign the informed consent.\n\nExclusion Criteria:\n\n1. Subjects with a known history of allergy, hypersensitivity, intolerance, or contraindication to any component of CART-BCMA or drugs that may be used in the study (including fludarabine, cyclophosphamide, tocilizumab); or subjects allergic to beta-lactam antibiotics; or subjects with a history of severe allergic reactions.\n2. Subjects who have previously received any CAR-T therapy or BCMA-targeted therapy.\n3. Subjects who have received the following anti-multiple myeloma (anti-MM) treatments within the specified time frame before apheresis:\n\n   * Small-molecule targeted therapy within 4 weeks or five half-lives, whichever was longer\n   * Macromolecular drug therapy within 4 weeks or 2 half-lives (whichever is longer)\n   * Cytotoxic therapy or proteasome inhibitor within 2 weeks\n   * Immunomodulatory drug therapy within 1 week\n   * Radiotherapy within 1 week\n4. Subjects who have received any investigational drug within 4 weeks prior to apheresis or are concurrently participating in another clinical study (except for the following: subjects participating in observational, non-interventional clinical studies, or those in the follow-up period of an interventional clinical study).\n5. Patients who have received autologous hematopoietic stem cell transplantation (ASCT) within 12 weeks prior to apheresis or have previously received allogeneic stem cell transplantation (with no time limit).\n6. Subjects who have received live vaccines or attenuated vaccines within 4 weeks prior to CART-BCMA apheresis.\n\n   Note: Administration of inactivated viral vaccines for seasonal influenza via injection is permitted; however, intranasal attenuated live influenza vaccines are not permitted.\n7. Subjects who have received any of the following treatments within 7 days prior to apheresis, or are judged by the investigator to require long-term receipt of such treatments during the study:\n\n   * Cumulative corticosteroids use equivalent to ≥ 70 mg prednisone within 7 days prior to apheresis, or long-term receipt of therapeutic-dose corticosteroids during the study as judged by the investigator\n   * Immunosuppressive therapy\n   * Graft-versus-host disease therapy\n   * Central nervous system (CNS) prophylactic therapy\n8. Toxicities resulting from previous treatments (including peripheral neuropathy) have not fully resolved or stabilized to Grade 1 (per NCI-CTCAE v5.0), except for those judged by the investigator to not affect the patient's safe receipt of treatment (e.g., alopecia).\n9. Any clinically significant past or current history of CNS disorders, such as altered mental status, psychosis, dementia, neurocognitive, neurodegenerative, or neuroinflammatory diseases (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis), epilepsy, seizures, hemiplegia, aphasia, stroke, subarachnoid hemorrhage or other CNS hemorrhage, and severe traumatic brain injury. For subjects with history of such CNS alterations, they must have fully recovered at least 1 year before administration.\n10. Presence of meningeal, brainstem, spinal cord metastasis and\u002For compression, or active CNS metastasis; or suspected involvement of the CNS or meninges by multiple myeloma (MM), confirmed by magnetic resonance imaging (MRI) or computed tomography (CT).\n11. Suspected involvement of the CNS or meninges by MM (confirmed by MRI or CT), or presence of other active CNS diseases.\n12. Patients with plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes), or amyloidosis at screening.\n13. Cardiac diseases: Current heart failure (New York Heart Association \\[NYHA\\] classification ≥ Class II, Appendix 2); severe cardiac diseases as determined by the investigator; myocardial infarction occurring ≤ 6 months before apheresis; unstable angina pectoris, severe arrhythmia (as judged by the investigator), or coronary artery bypass grafting (CABG) performed ≤ 3 months before apheresis.\n14. Poorly controlled hypertension (systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg), or a history of hypertensive crisis or hypertensive encephalopathy.\n15. Patients who have undergone major surgery (other than diagnostic procedures or biopsies) or plasmapheresis within 4 weeks before apheresis or are expected to undergo major surgery during the study. Note: Patients scheduled for surgical procedures under local anesthesia may participate in the study. Kyphoplasty or vertebroplasty is not considered major surgery.\n16. Subjects currently receiving thrombolytic, anticoagulant, or antiplatelet therapy.\n17. Subjects with infections requiring intravenous antibiotic administration or hospitalization.\n18. Subjects with active hepatitis B; subjects positive for hepatitis C virus (HCV) antibody and positive for HCV RNA; subjects positive for human immunodeficiency virus (HIV) antibody; subjects positive for syphilis screening antibody;\n\n    a) Non-active\u002Fasymptomatic carrier, chronic, or active HBV-infected subjects may be enrolled if they meet the following criteria: HBV deoxyribonucleic acid (DNA) \\\u003C 500 IU\u002FmL (or 2500 copies\u002FmL) at screening.\n19. Pregnant or lactating women.\n20. Subjects diagnosed with or treated for other invasive malignant tumors except multiple myeloma, except for the following cases: non-melanoma skin cancer that has been surgically removed, cured cervical carcinoma in situ, localized prostate cancer, low-stage bladder cancer, ductal carcinoma in situ of the breast, or malignant tumors with no recurrence and no treatment within 2 years before enrollment.\n21. Subjects deemed by the investigator to be unsuitable for participation in this clinical study due to any clinical or laboratory abnormalities or other reasons.",{"count":404,"type":22},3,[380],"A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma.",[408],"Relapsed\u002FRefractory Multiple Myeloma (MM)",[410,401,411,412],"Relapsed\u002FRefractory Multiple Myeloma","BCMA","CAR T-cell","2026-03-04",{"date":415,"type":42},"2026-03-09",{"date":417,"type":22},"2026-06-01",{"date":419,"type":22},"2029-06-01",{"name":48,"class":49},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":430,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":50},"100587781","the-therapeutic-effect-of-curcumin-in-nanogels-compared-to-01-fao-in-the-management-of-oral-lichen-planus-100587781","NCT06932848","The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus","The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% Fluocinolone Acetonide Oral Paste in the Management of Atrophic-Erosive Oral Lichen Planus","Inclusion Criteria:\n\n* Age 18 years or older\n* Ability to provide written informed consent\n* Clinically and histopathologically confirmed diagnosis of erosive or atrophic oral lichen planus (OLP)\n* Presence of symptoms (NRS pain score \\> 0 at baseline)\n* Ability to communicate and follow instructions\n* Willingness to apply oral paste treatment and comply with study protocol\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Current orthodontic treatment\n* Uncontrolled diabetes mellitus (HbA1c \\> 7% or FPG \\> 130 mg\u002FdL)\n* Use of anticoagulants or antiplatelet agents\n* Severe dry mouth (Challacombe score \\> 7)\n* History of gastric ulcers, duodenal ulcers, or gallstones\n* Presence of any active malignancy or infection\n* Use of topical\u002Fsystemic treatment for OLP in the past 2 weeks\n* Current use of immunosuppressants\n* Known allergy to corticosteroids or herbal agents such as turmeric\n* Diagnosis of oral lichenoid contact lesion or graft-versus-host disease (GVHD)\n* History of allogeneic bone marrow transplantation\n* Current smokers",{"count":429,"type":22},30,[91],"This randomized, double-blind clinical trial evaluates the therapeutic effects of curcumin in nanogels compared to 0.1% fluocinolone acetonide oral paste in the management of atrophic-erosive oral lichen planus (OLP). The study aims to determine whether curcumin nanogels, a natural treatment with enhanced bioavailability, are as effective and better tolerated than standard corticosteroid therapy.",[433],"Oral Lichen Planus",[435,436,437,438,439,440],"Atrophic-Erosive Oral Lichen Planus","Curcumin","Nanogels","Fluocinolone Acetonide","Mucosal Disease","Autoimmune Disease",{"date":442,"type":42},"2026-03-06",{"date":444,"type":42},"2025-06-01",{"date":446,"type":22},"2026-06-30",{"name":48,"class":49},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":18,"minAge":456,"maxAge":19,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":463,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":404},"100599010","phase-1-clinical-trial-of-cmd63-chimeric-antigen-receptor-t-cell-car-t-cell-in-children-with-acute-lymphoblastic-leukemia-all-100599010","NCT07078929","Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)","Safety and Preliminary Efficacy of CD19 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD63) in Relapse and Refractory Pediatric B-cell Acute Lymphoblastic Leukemia","CMD63","Inclusion Criteria:\n\n1. Participants must have relapsed, or refractory ALL treated with at least one lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve complete remission with the last regimen.\n\n   \\- Participant with Philadelphia Chromosome positive ALL are eligible if the progressed, had stable disease or relapsed after one line of therapy including tyrosine kinase inhibitors (TKIs)\n2. The participant's disease must be CD19 positive either by immunohistochemistry or flow cytometry analysis\n3. Age 1 - 18 years\n4. Sex: Male or Female\n5. Performance status: Lansky or Karnofsky score greater than or equal to 50\n6. Normal organ function:\n\n   * AST (SGOT) less 5 times the upper limit of normal (ULN)\n   * ALT (SGPT) less 5 times the upper limit of normal (ULN)\n   * Total bilirubin less 3 times the upper limit of normal (ULN)\n   * Creatinine less 5 times the upper limit of normal (ULN)\n   * SpO2 room air greater than or equal to 90%\n7. Prior therapy wash-out before planned leukapheresis 7.1 Greater than or equal to 7 days post last chemotherapy\u002Fbiologic therapy administration 7.2 Three half-lives or 30 days, whichever is shorter after the last dose of antitumor antibody therapy 7.3 At least 30 days from most recent cellular infusion 7.4 All systemically administered corticosteroid treatment therapy must be stable or decreasing within 1 week prior to enrollment with a maximum of 0.5 mg\u002Fday dose of methylprednisolone. Corticosteroid physiologic replacement therapy is allowed\n8. Participants and\u002For care givers must have the ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Active GVHD that required systemic immunosuppressant with 4 weeks of enrollment\n2. History of active malignancy other than non-melanoma skin cancer and carcinoma in situ (e.g. cervix, bladder, breast).\n3. Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities, Graft Versus Host Disease or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n4. Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with potential for teratogenic or abortifacient effect. Women of child bearing potential must have negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of mother with CAR-T cells, breast feeding should be discontinued. These potential risks may also apply to other agents used in this study. Participants of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving CAR-T cell infusion.\n5. Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy.\n6. Serologic status reflecting active HIV, hepatitis B or C infection. Participants that are positive for hepatitis B core antibody, hepatitis B surface antigen or hepatitis C antibody must have negative PCR prior to enrollment.\n7. Participants who have a history of anaphylactic reaction to albumin.","1 Year",{"count":333,"type":22},[279],"A Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.",[461,462],"Relapse B Acute Lymphoblastic Leukemia","Refactory Childhood Acute Lymphoblastic Leukemia",[464,465,466,467,468,469],"CAR T cell","CD19","IL-7 receptor alpha","Chimeric antigen receptor T cell","Adoptive cellular therapy","B-cell acute lymphoblastic leukemia","2026-02-26",{"date":472,"type":42},"2026-03-02",{"date":474,"type":42},"2026-01-01",{"date":476,"type":22},"2028-09-01",{"name":48,"class":49},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":456,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":494,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":50},"100563167","phase-1-safety-and-efficacy-of-cmd03-car-t-cell-in-children-with-relapse-or-refractory-solid-tumors-100563167","NCT06612645","Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors","Safety and Efficacy of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD03) in Relapse and Refractory Pediatric Solid Tumors","CMD03","Inclusion Criteria:\n\n1. Participants must have B7-H3 positive solid tumor with measurable disease.\n\n   \\- B7-H3 expression will be evaluated by standard immunohistochemistry (IHC) or flow cytometry using a previously obtained sample.\n2. Evidence of relapsed or refractory disease after standard first-line therapy\n3. Age 1 - 25 years\n4. Sex: Male or female\n5. Performance status: Lansky or Karnofsky score not less than 50\n6. Life expectancy not less than 12 weeks\n7. Normal organ function\n\n   * AST (SGOT) below 5 times the upper limit of normal (ULN)\n   * ALT (SGPT) below 5 times the upper limit of normal (ULN)\n   * Total bilirubin below 3 times the upper limit of normal (ULN)\n   * Creatinine below 5 times the upper limit of normal (ULN)\n   * SpO2 room air not less than 90%\n8. Prior therapy wash-out before planned leukapheresis\n\n   * Not less than 7 days post last chemotherapy\u002Fbiologic therapy administration\n   * 3 half-lives or 30 days, whichever is shorter after the last dose of antitumor antibody therapy\n   * At least 30 days from most recent cellular infusion\n   * All systemically administered corticosteroid treatment therapy must be stable or decreasing within 1 week prior to enrollment with a maximum of 0.5 mg\u002Fkg\u002Fday dose of methylprednisolone. Corticosteroid physiologic replacement therapy is allowed\n9. Participants and\u002For legal guardians must have the ability to understand and willingness to sign a written informed consent and\u002For assent document\n\nExclusion Criteria:\n\n1. Presence of greater than or equal to grade 3 cardiac dysfunction or symptomatic arrythmia requiring intervention\n2. Presence of primary immunodeficiency or bone marrow failure syndrome\n3. Presence of uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n4. Pregnant or breastfeeding women were excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. Participants of childbearing or child-fathering potential must be willing to practice birth control from the time of enrollment in this study and for four months after receiving CAR-T-cell infusion.\n5. Serologic status reflecting active HIV, hepatitis B or C infection. Participants who are positive for hepatitis B core antibody, hepatitis B surface antigen or hepatitis C antibody must have negative PCR prior to enrollment.","25 Years",{"count":488,"type":22},9,[279],"A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.",[492,493],"Pediatric Cancers","Solid Tumor Pediatric",[464,495,466,467,468,496],"B7H3","Solid tumor pediatric",{"date":472,"type":42},{"date":499,"type":42},"2025-04-01",{"date":501,"type":22},"2028-12-01",{"name":48,"class":49},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":4},"100621696","early-phase-1-comparison-of-postoperative-pain-after-pulpotomy-performed-with-versus-without-dental-operating-microscope-in-carious-mature-permanent-teeth-100621696","NCT07373977","Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Mature Permanent Teeth","Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Mature Permanent Teeth : A Randomized Controlled Trial","Inclusion Criteria:\n\n* Healthy patients aged at least 18 years old with deep or extremely deep carious lesions in mature permanent teeth diagnose with symptomatic irreversible pulpitis. Diagnoses are confirmed using EPT and cold tests. Pulpal and periapical diagnoses are based on terminology from the American Association of Endodontists (AAE, 2013)20.\n* Posterior teeth with moderate or severe pain according to The NRS (Numeric Rating Scale) According to this scale, the level of pain is documented in the range of 0-10 numerically and verbally as no pain (0), mild pain, non-disruptive to routine activities (1-3), moderate pain that interferes with daily life but no need analgesics intake (4-6) and severe pain that significantly disrupts normal acitivities requiring analgesic intervention (7-10).\n* Teeth that response negatively to percussion and palpation tests.\n* Teeth are restorable with direct composite restoration.\n\nExclusion Criteria:\n\n* Teeth with subgingival caries and\u002For clinical attachment loss more than 3 mm and probing depth more than 4 mm.\n* Negative responses to pulp sensibility tests, presence of sinus tracts, swelling, non-restorable crowns, immature roots, or no pulp exposure following complete caries removal in case of pre-operative diagnosis as asymptomatic irreversible pulpitis.\n* Patients with systemic diseases involving bleeding disorders such as hemophilia, Von Willebrand disease, platelet disorders. And patients under taking all kind of anticoagulant and anti-platelet.\n* Patients who had taken analgesics or anti-inflammatory drugs within the previous 24 hours. If necessary, record how many and dose that taken.\n* Patients taking opioids.\n* Known allergies to non-steroidal anti-inflammatory drugs (NSAIDs).\n* Pregnant or lactating patients.\n* Teeth with pulpal obliteration.\n* Necrotic pulp is found after access opening\n* Bleed cannot be stopped within 8 minutes after full pulpotomy",{"count":511,"type":22},82,[380],"The goal of this \\[randomized clinical trials\\] is to investigate the effect of using dental operating microscope incorperated in full pulpotomy procedure in mature carious posterior teeth.\n\nThe main questions it aims to answer are:\n\ninvestigate postoperative pain levels.\n\ninvestigate the quality of life of patient after treatment.\n\nIf there is a comparison group: Researchers will compare the pulpotomy procedure with and without using dental operating microscope.\n\nParticipants will will be asked to do\n\n* Pain evaluation with numerical rating scale\n* OHIP 14 survey before and after treatment",[515],"Carious Exposure of Pulp",[385,517,518],"Dental operating microscope","post-operative pain","2026-01-28",{"date":521,"type":42},"2026-01-30",{"date":523,"type":22},"2026-02-10",{"date":78,"type":22},{"name":48,"class":49},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":330,"minAge":19,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":534,"briefSummary":535,"conditions":536,"keywords":541,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":50},"100599372","phase-2-transdermal-ethinyl-estradiol-and-norelgestromin-for-irregular-bleeding-in-contraceptive-implant-users-100599372","NCT07083635","Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users","Transdermal Ethinyl Estradiol and Norelgestromin for Treating Irregular Vaginal Bleeding in Contraceptive Implant Users: A Randomized, Double-Blind, Controlled Trial","Inclusion Criteria:\n\n* Women aged 18 years and older\n* Regular menstrual cycles : at least 1 cycle prior to contraceptive implant insertion\n* Normal pelvic examination and transvaginal ultrasound results\n* Normal cervical cancer screening within the past 3 years\n* Irregular vaginal bleeding defined as: Bleeding for more than 8 consecutive days, or Bleeding-free intervals of 15 days or less\n\nExclusion Criteria:\n\n* Previous treatment for irregular vaginal bleeding within the past 3 months\n* Pregnancy\n* Contraindications to estrogen or progestin use\n* Allergy to estrogen or progestin\n* Allergy to hormonal patches\n* Heavy vaginal bleeding causing anemia symptoms such as: Fatigue\u002FFainting\u002FDizziness",{"count":112,"type":22},[61],"The goal of this clinical trial is to evaluate the effectiveness of transdermal contraceptive patches in treating irregular vaginal bleeding in women over 18 years old who are using contraceptive implants and experiencing abnormal vaginal bleeding. The main questions it aims to answer are:\n\n* Does transdermal ethinyl estradiol and norelgestromin patch effectively treat irregular vaginal bleeding caused by contraceptive implants compared to placebo?\n* What proportion of participants will report cessation of vaginal bleeding during treatment and remain bleeding-free at day 14 of treatment?\n* What is the safety profile and adherence rate of the transdermal patch treatment?\n\nResearchers will compare participants receiving active hormonal patches (ethinyl estradiol 600 mcg + norelgestromin 6 mg) to those receiving placebo patches to see if the hormonal treatment effectively stops irregular vaginal bleeding.\n\nParticipants will:\n\n* Apply transdermal patches for 21 days (changing patch every 7 days - total of 3 patches)\n* Attend follow-up visits at days 7, 14, 21, and 3 months (day 14 in-person, others via telephone)\n* Complete bleeding diaries and report any side effects\n* Follow-up schedule:\n\nDay 7: Telephone follow-up to assess bleeding pattern, side effects, and patch adherence Day 14: In-person visit at the clinic for comprehensive evaluation including bleeding assessment, side effects monitoring, and adherence check Day 21: Telephone follow-up to evaluate treatment completion, ongoing bleeding status, and need for additional treatment 3 months: Final telephone follow-up to assess long-term outcomes and recurrence of bleeding",[537,538,539,540],"Menstruation Disturbances","Metrorrhagia","Uterine Hemorrhage","Contraception Behavior",[542,543,544,545,546,547,548,549,550,551,552],"Contraceptive implant","Abnormal vaginal bleeding","Bothersome vaginal bleeding","Irregular vaginal bleeding","Transdermal hormonal contraception","Ethinyl estradiol","Norelgestromin","Abnormal uterine bleeding","Contraceptive-induced bleeding","Combined hormonal contraception","Hormonal contraceptive patch","2025-12-09",{"date":555,"type":42},"2025-12-10",{"date":557,"type":42},"2025-07-29",{"date":321,"type":22},{"name":48,"class":49},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":571,"conditions":572,"keywords":579,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":597,"locationsCount":50},"100607937","thai-painpredict-validation-study-100607937","NCT07195045","Thai PainPREDICT Validation Study","Thai Version of PainPREDICT: Translation, Validation, and Mobile Application Development for Screening Painful Diabetic Neuropathy in Diabetes Patients","PainPREDICT-Th","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed with type 1 diabetes mellitus or type 2 diabetes mellitus.\n* Able to communicate in Thai.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of neuropathy due to other causes (e.g., alcohol, chemotherapy, HIV, other systemic diseases).\n* Significant cognitive impairment or neurological conditions that prevent comprehension of the questionnaire.\n* Severe psychiatric illness that interferes with study participation.",{"count":569,"type":22},277,[91],"Painful diabetic neuropathy (PDN) is one of the most common and disabling complications of diabetes mellitus, substantially affecting quality of life, daily functioning, and health system burden. Early identification of PDN is crucial for timely treatment, prevention of complications such as foot ulcers and amputations, and for reducing healthcare costs. However, in Thailand there are limited culturally adapted and validated tools for screening PDN. PainPREDICT is an internationally validated questionnaire designed to characterize neuropathic pain profiles, but its adaptation for Thai patients has not yet been undertaken. In parallel, the use of mobile health technologies (mHealth) has the potential to expand access to screening and monitoring of chronic conditions, particularly in resource-limited settings.",[573,574,575,576,577,578],"Painful Diabetic Neuropathy (PDN)","Diabetic Neuropathy, Distal Symmetric Polyneuropathy (Manifestation)","Type 1 Diabetes Mellitus (T1DM)","Type 2 Diabetes Mellitus (T2DM)","Neuropathic Pain","Diabetes Complications",[580,581,582,583,584,585,586,587,588,589,578,590],"PainPREDICT","Painful Diabetic Neuropathy","Diabetic Neuropathy","Neuropathic Pain Questionnaire","Mobile Health (mHealth)","Questionnaire Validation","Screening Tool","Thai Population","Cross-Cultural Adaptation","Digital Health Application","Neuropathy Screening","2025-09-29",{"date":593,"type":42},"2025-10-03",{"date":595,"type":42},"2025-08-28",{"date":102,"type":22},{"name":48,"class":49},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":605,"targetDuration":606,"studyType":142,"phases":4,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":50},"100607714","patient-reported-outcomes-and-associated-factors-following-endodontic-emergency-treatment-100607714","NCT07192146","Patient Reported Outcomes and Associated Factors Following Endodontic Emergency Treatment","Patient Reported Outcomes and Associated Factors Following Endodontic Emergency Treatment: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age 18 years or older\n* Presence of moderate to severe pain as measured by a Numerical Rating Scale (NRS) score ≥ 4\n* Pain of endodontic origin confirmed through clinical and\u002For radiographic examination\n\nExclusion Criteria:\n\n* Refused or were unable to provide informed consent or complete the questionnaire\n* Were currently or recently taking immunosuppressive agents, long-term anti-inflammatory medications, or antibiotics\n* Had non-endodontic or mixed-origin pain\n* Had already initiated endodontic treatment on the affected tooth",{"count":140,"type":22},"7 Days","This study aims to analyze the improvement of postoperative pain and Oral Health-Related Quality of Life (OHRQoL) following endodontic emergency treatment, as well as the contributing factors affecting the change including age, gender, tooth type, dental arch, pulpal status, percussion pain, radiographic evidence of periapical lesions, type of emergency treatment (pulpotomy \u002F partial pulpectomy \u002F complete pulpectomy), and occlusal adjustment.",[609],"Moderate to Severe Endodontic Pain","2025-09-21",{"date":612,"type":42},"2025-09-25",{"date":614,"type":42},"2023-08-17",{"date":616,"type":22},"2025-10",{"name":48,"class":49},{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":624,"enrollmentInfo":625,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":628,"conditions":629,"keywords":631,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":50},"100598110","non-invasive-brain-stimulation-and-exercise-intervention-for-patients-with-motor-neuron-disease-100598110","NCT07067229","Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease","Inclusion Criteria:\n\n* Participants aged between 18 and 80 years\n* Diagnosed with any type of motor neuron disease (MND)\n* Have mild to moderate severity, as assessed by the Sinaki-Mulder scale, with a severity level between 1 and 3\n\nExclusion Criteria:\n\n* History of other neurological disorders, such as stroke\n* Use of ventilatory support\n* Severe dementia","80 Years",{"count":626,"type":22},100,[91],"Motor neuron disease (MND) is a progressive neurological disorder involving degeneration of motor neurons, leading to muscle weakness, speech and swallowing difficulties, and respiratory failure. This study aims to develop a novel treatment approach combining personalized repetitive transcranial magnetic stimulation (rTMS) with mixed reality (MR) exercise-based games (exergames) to slow disease progression and improve quality of life. In this randomised controlled trial study will compare three groups: (1) rTMS with MR exercise (personalized intervention), (2) rTMS with MR exercise (standard intervention), and (3) sham rTMS with MR exercise. Outcomes will be assessed at baseline, 3 months, and 6 months post intervention. The long-term goal is to implement this approach in clinical settings to enhance care for people with MND.",[630],"ALS (Amyotrophic Lateral Sclerosis)",[632,633,634,635],"Amyotrophic Lateral Sclerosis","Transcranial Magnetic Stimulation","Intervention","Augmented Reality",{"date":612,"type":42},{"date":638,"type":42},"2025-08-01",{"date":640,"type":22},"2027-12-30",{"name":48,"class":49},{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":650,"targetDuration":651,"studyType":142,"phases":4,"briefSummary":652,"conditions":653,"keywords":654,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":661,"leadSponsor":663,"locationsCount":50},"100606467","amyotrophic-lateral-sclerosis-registry-in-thailand-100606467","NCT07175935","Amyotrophic Lateral Sclerosis Registry in Thailand","A Prospective, Multicenter Registry Study of Amyotrophic Lateral Sclerosis in Thailand","Thai ALS Regis","Inclusion Criteria:\n\n* Diagnosis of ALS according to El Escorial or Gold Coast criteria\n* Age ≥ 18 years\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n* Patients unwilling to provide informed consent\n* Patients with alternative diagnoses mimicking ALS",{"count":626,"type":22},"10 Years","This is a prospective, observational, multicenter registry designed to collect comprehensive clinical, genetic, and outcome data from patients diagnosed with amyotrophic lateral sclerosis (ALS) across Thailand. The registry will establish a national dataset to describe epidemiology, clinical presentation, progression, and treatment outcomes, and will serve as a platform for future clinical and translational research.",[630],[632,655,656],"Epidemiological","Natural History","2025-09-14",{"date":659,"type":42},"2025-09-16",{"date":76,"type":42},{"date":662,"type":22},"2030-12-31",{"name":48,"class":49},{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":668,"acronym":669,"eligibilityCriteria":670,"healthyVolunteers":136,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":671,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":673,"conditions":674,"keywords":676,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":50},"100518780","icu-fluid-utilization-survey-in-southeast-asia-100518780","NCT06034990","ICU Fluid Utilization Survey in Southeast Asia","Fluid-SEA","Inclusion Criteria:\n\n1. Specialty must be in Anesthesiology, Surgery, Critical Care Medicine, Pulmonology, Nephrology, Internal Medicine, General Practitioner\n2. Practice must be in Southeast Asia hospitals\n3. Must work in Surgical ICU, Medical ICU , and\u002For Mixed ICU\n\nExclusion Criteria:\n\n1.Physicians who worked in cardiac, neurology or pediatric ICUs",{"count":672,"type":22},1000,"The objective of this study is to examine the use of different types of fluids for resuscitation in different phases of fluid management in 3 types of critically ill patients including (1) not bleeding, not septic but need volume resuscitation (representing normal condition), (2) bleeding but not septic (representing normal vascular integrity but with a loss of intravascular colloids), (3) septic (representing the condition with increase vascular permeability and endothelium damage) in the ICU within Southeast Asia.\n\nThe data are collected by a 10-min online survey administered to included physicians which will be distributed via multiple online channels through representatives of each countries.",[675],"Critical Illness",[677,678,679,680,681,682],"Crystalloids","Colloids","Fluid resuscitation","Intensive care unit","Sepsis","Bleeding","2025-08-13",{"date":685,"type":42},"2025-08-17",{"date":687,"type":42},"2024-01-31",{"date":689,"type":22},"2026-09-30",{"name":48,"class":49},""]